A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (L-001079038) in Patients with Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) - L-001079038 in Relapsed DLBC

Merck Sharp & Dohme Limited0 个研究点目标入组 50 人开始时间: 2005年2月10日最近更新: 2019年12月16日

试验速览

暂无简介。

•Eligible patients must be =18 years with relapsed DLBCL (de novo or transformed)following standard first line chemotherapy and at least one salvage systemic therapy. Patients who have disease that is refractory to their last chemotherapy regimen are not eligible. Other eligibility criteria include: 3 months or longer without evidence of progression on the most recent treatment; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2; = 4 weeks from prior chemotherapy, radiation therapy, major surgery, or other investigational anticancer therapy; and adequate hematologic (absolute neutrophil count >1000/mm3, platelets > 75,000 /mm3), hepatic and renal function.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patients to be excluded from the trial if:
•had prior treatment with any HDAC inhibitor (e.g., Depsipeptide, MS-275, LAQ 824);
•had a response or stable disease less than 3 m to the most recent treatment;
•have failed more than 3 prior regimens ;
•have had an allogenenic transplantation.
•have certain co-mobility including HIV infection.

发起方

Merck Sharp & Dohme Limited